CeriBell (NASDAQ:CBLL) CEO Sells 25,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $18.82, for a total transaction of $470,500.00. Following the transaction, the chief executive officer directly owned 798,135 shares of the company’s stock, valued at approximately $15,020,900.70. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.59, for a total transaction of $414,750.00.
• On Friday, November 21st, Xingjuan Chao sold 50,000 shares of CeriBell stock. The stock was sold at an average price of $15.13, for a total value of $756,500.00.

CeriBell Stock Performance

CBLL traded up $0.76 during trading on Monday, hitting $20.48. The stock had a trading volume of 318,782 shares, compared to its average volume of 304,056. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a one year low of $10.01 and a one year high of $32.75. The firm has a market cap of $759.62 million, a price-to-earnings ratio of -13.56 and a beta of 1.30. The company has a 50 day moving average price of $13.44 and a 200-day moving average price of $14.37.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. As a group, research analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CeriBell in the 3rd quarter valued at about $33,000. Tower Research Capital LLC TRC raised its position in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after acquiring an additional 3,502 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of CeriBell during the third quarter valued at about $135,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen reduced their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Raymond James Financial initiated coverage on CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. JPMorgan Chase & Co. cut their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.17.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.